Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 22, 2017
Pharmacy Choice - News - Generic Drugs - July 22, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

6/22/17 - Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access; Public Meeting; Request for Comments
SUMMARY: The Food and Drug Administration is announcing the following meeting: "The Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access." DATES: The meeting will be held on July 18, 2017, from 9 a.m. to 5 p.m. The deadline for submitting comments regarding this meeting is September 18, 2017. ADDRESSES: The meeting will be held
6/22/17 - Aiming for Amgen
The U.S. Supreme Court recently ruled that companies developing copies of these drugs, called biosimilars because exact generic copies can't be made, no longer must wait six months after getting regulatory approval to start selling them. Edward Jones analyst Ashtyn Evans says that will speed up competition for some Amgen medicines, which could redu
6/22/17 - Alembic Pharmaceuticals gets USFDA nod for Amantadine Hydrochloride Capsules [India Infoline News Service]
Alembic Pharmaceuticals on Thursday announced that it has received approval from the US Food& Drug Administration for its Abbreviated New Drug Application for Amantadine Hydrochloride Capsules, USP, 100 mg. Alembic Pharmaceuticals on Thursday announced that it has received approval from the US Food& Drug Administration for its Abbreviated New Drug.
6/22/17 - FDA accepts application for generic version of Advair Diskus
The FDA has accepted Sandoz's New Drug Application for fluticasone propionate / salmeterol combination product, a generic version of Advair Diskus...
6/22/17 - Lannett Receives Approval For Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg And 10 mg/300 mg
Lannett Company, Inc. today announced that it received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg, the therapeutic equivalent to the reference standard drug, Hydrocodone Bitartrate and Acetaminophe
6/22/17 - Sen. Grassley Encourages FDA Commissioner to Consider Proposals to Expand Access to Affordable Prescription Drugs
Gottlieb previously testified that the FDA would work to curtail gaming of FDA regulations by drug makers, improve the approval process for generic drugs and eliminate the FDA's backlog of applications for generics. The Creating and Restoring Equal Access to Equivalent Samples Act, which Grassley introduced with Senator Patrick Leahy, would address
6/21/17 - ACETO Subsidiary, Rising Pharmaceuticals, Launches Chlorthalidone Tablets, 25 mg and 50 mg, and Glipizide Extended Release Tablets, 2.5 mg, 5 mg and 10 mg
Release date- 20062017- PORT WASHINGTON, N.Y.- ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched an FDA approve
6/21/17 - ACETO Subsidiary, Rising Pharmaceuticals, Launches Chlorthalidone Tablets, 25 mg and 50 mg, and Glipizide Extended Release Tablets, 2.5 mg, 5 mg and 10 mg [Tehran Times (Iran)]
-ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched an FDA- approved generic version of Chlorthalidone Tablets,
6/21/17 - Alembic receives U.S. FDA approval for Candesartan Cilexetil Tablets [India Infoline News Service]
Alembic Pharmaceuticals has received US Food& Drug Administration approval for its Abbreviated New Drug Application for Candesartan Cilexetil Tablets, 32 mg, the company informed the bourses on Wednesday. Alembic Pharmaceuticals has received US Food& Drug Administration approval for its Abbreviated New Drug Application for Candesartan Cilexetil...
6/21/17 - Concordia International Corp. Provides Update on Development of Long-Term Growth Strategy
-Concordia International Corp., an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced an update on the development of its long-term growth strategy. To support the development and execution of this strategy, the Company has engaged Perella Weinberg Partners LP to provide financial..
6/21/17 - Credence Research: Global Biosimilars Market Is Expected To Reach US$ 25.83 Bn By 2025
Global Biosimilars Market Is Expected To Reach US$ 25.83 Bn By 2025. The latest market report published by Credence Research, Ltd. "Global Biosimilars Market- Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2017- 2025," the Biosimilars market was valued at US$ 3.52 Bn in 2016, and is expected to reach US$ 25.83
6/21/17 - FDA Voice Blog: FDA Working to Lift Barriers to Generic Drug Competition
While FDA doesn't have a direct role in drug pricing, we can take steps to help address this problem by facilitating increased competition in the market for prescription drugs through the approval of lower-cost, generic medicines. We could see even greater cost savings if we helped more safe and effective generic drugs get to market sooner, after p
6/21/17 - Grassley Encourages FDA Commissioner to Consider Proposals to Expand Access to Affordable Prescription Drugs
Gottlieb previously testified that the FDA would work to curtail gaming of FDA regulations by drug makers, improve the approval process for generic drugs and eliminate the FDA's backlog of applications for generics. The Creating and Restoring Equal Access to Equivalent Samples Act, which Grassley introduced with Senator Patrick Leahy, would address
6/21/17 - Olon SpA P&R Group Acquires Ricerca Biosciences Chemical Division In Ohio USA
By a News Reporter-Staff News Editor at Biotech Week Olon S.p.A., a world leading Active Pharmaceutical Ingredients contract development and manufacturing organization and Generics supplier, announced the acquisition of Ricerca Biosciences' Chemical Division of the contract research and CDMO based in Concord, Ohio, USA. This acquisition strengthe
6/21/17 - Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications
FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601.. SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 in this document have informed FDA that these drug products
6/20/17 - AAM praises Supreme Court Ruling granting access to biosimilars
The Association for Accessible Medicines (AAM) applauded the US Supreme Court's decision this week in Sandoz Inc. v. Amgen Inc. that will help speed patient access to biosimilar versions of expensive brand-name biologic medicines.
6/20/17 - Abbreviated New Drug Applications: Pre-Submission Facility Correspondence Associated with Priority Submissions; Draft Guidance for Industry;...
SUMMARY: The Food and Drug Administration is announcing the availability of a draft guidance for industry entitled "ANDAs: Pre-Submission Facility Correspondence Associated with Priority Submissions." DATES: Although you can comment on any guidance at any time, to ensure that the Agency considers your comment on this draft guidance before it begins
6/20/17 - ACETO Subsidiary, Rising Pharmaceuticals, Launches Chlorthalidone Tablets, 25 mg and 50 mg, and Glipizide Extended Release Tablets, 2.5 mg, 5 mg and 10 mg
ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched an FDA- approved generic version of Chlorthalidone Tablets,
6/20/17 - ANI Pharmaceuticals Announces Launch of Diphenoxylate HCl and Atropine Sulfate Tablets
ANI Pharmaceuticals, Inc. today announced the launch of Diphenoxylate HCl and Atropine Sulfate Tablets, 2.5 mg/0. 025 mg. The annual U.S. market for Diphenoxylate HCl and Atropine Sulfate Tablets is approximately $56 million, per IMS Health. ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and
6/20/17 - Axis Biotec Announces the Construction of an Innovative Tobacco-Based Biopharmaceutical Expression and Pilot Manufacturing Facility in Brazil
RIO DE JANEIRO Construction will begin this summer on a state-of-the-art biopharmaceutical lab and pilot production facility in Rio de Janeiro that will support the development of key biosimilar and biobetter protein drugs for the Brazilian market, through a joint venture between Brazil- based Axis Biotec Brasil and Canadian biotech company Pla
6/20/17 - Biosimilars Market | Global Industry Outlook Analysis Report 2016-2023
The new research report onBiosimilars Marketoffered by DecisionDatabases.com provides Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 to 2023. The report on global biosimilars market evaluates the growth tr...
6/20/17 - Erythropoietin (EPO) Drugs Market is expected to reach USD 17.4 billion by 2025
The global erythropoietin drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cancer resulting in anemia is a major growth driver of this market. Introduction of novel drugs and their cheaper biosimilar formulations with enhanced effi
6/20/17 - Findings from L.H. Camacho and Co-Authors Reveals New Information on Drug Research (Current Status of Biosimilars in Oncology)
By a News Reporter-Staff News Editor at Cancer Weekly Current study results on Drugs and Therapies- Drug Research have been published. According to news reporting originating from Houston, Texas, by NewsRx editors, the research stated, "Four medicinal cancer biological blockbusters will end their patent lifespan by 2020. Our news editors obtained
6/20/17 - Generic drugs
I am an MS patient, and I rely on safe, affordable generic drugs to manage my health. Please help get the word out to the public about legislation like the CREATES Act and FAST Generics Act that will allow generic companies the access needed to samples to conduct drug product development and bioequivalence studies necessary for FDA approval.
6/20/17 - Novartis secures European approval for cancer treatment [Tehran Times (Iran)]
Novartis AG said Monday that it has received approval from the European Commission for a blood cancer treatment known as Rixathon, a biosimilar version of Roche AGs blockbuster Rituxan that generated around US $7.5 billion in sales last year. Sandoz, the biosimilar division of Swiss drugmaker Novartis, said the approval allows for the use of Rixath
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415